Table 1.
Female sex, n (%) | 11 (69%) |
Age, years, mean (range) | 58.4 (36.6-72.9) |
Disease duration, years, mean (range) | 9.6 (0.5-48.0) |
Rheumatoid factor positive, n (%) | 11 (69%) |
CCP-antibody positive, n (%) | 12 (75%) |
Erosive disease, n (%) | 7 (44%) |
Disease activity (DAS28), n (%) | |
Moderate | 13 (81%) |
High | 3 (19%) |
csDMARD regimen, n (%) | |
Triple | 6 (37%) |
Double | 7 (44%) |
Single | 3 (19%) |
Low-dose prednisolone, n (%) | 8 (50%) |
CCP, cyclic citrullinated peptide; DAS28, composite Disease Activity Score for 28 joints based on the C-reactive protein level (DAS28-4[CRP]); csDMARD, conventional systemic disease-modifying antirheumatic drug; n, number of patients.